Ufp Technologies INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
UFP Technologies announced a 15.1% increase in net sales for Q2 2026, driven by growth in key medical sub-markets and improved operating efficiencies.
NASDAQ
UFP Technologies reported a 4.1% increase in net sales to $154.2 million for the first quarter of 2026, driven by growth in the medical device market.
NASDAQ
UFP Technologies reports a 6.5% increase in Q3 net sales to $154.6 million, primarily driven by recent acquisitions, despite labor inefficiencies impacting organic growth.
NASDAQ
UFP Technologies announced significant revenue and net income increases for Q2 2025, primarily fueled by recent strategic acquisitions in the medical market, despite some gross margin compression.
NASDAQ
10-Q: UFP Technologies Reports Strong Q1 2025 Results Driven by Medical Market Growth and Acquisitions
UFP Technologies' Q1 2025 net sales increased by 41.1% year-over-year, primarily driven by growth in the medical market and contributions from recent acquisitions.
NASDAQ
UFP Technologies' Q3 2024 results show significant growth in net sales and operating income, primarily driven by recent acquisitions and organic growth in the medical market.
NASDAQ
UFP Technologies saw an 8.8% increase in net sales for the first half of 2024, primarily driven by growth in the medical market, and completed several strategic acquisitions.
NASDAQ
UFP Technologies saw a 7.4% increase in organic revenue in the first quarter of 2024, primarily driven by growth in the medical sector, particularly in robotic surgery and infection prevention products.